Envista (NVST) Stock Price, News & Analysis

Company Overview

Envista Holdings Corporation is a global dental products and technologies company headquartered in Brea, California. The company develops, manufactures and markets products used by dentists, dental specialists, dental laboratories and other oral-care professionals.

Envista’s portfolio includes dental imaging and diagnostic systems, digital dentistry and CAD/CAM solutions, dental implants, orthodontic brackets and wires, clear aligner products, endodontic instruments, restorative materials, infection-prevention products and other dental consumables. Its principal brands include KaVo, Kerr, DEXIS, Nobel Biocare and Ormco.

Envista was established in 2019 when Danaher separated its dental businesses into an independent publicly traded company. The company serves customers through direct sales organizations and distributors across North America, Europe, Asia and other international markets.

Key Stats

• Today's Range: $23.60 to $24.13
• 50-Day Range: $23.38 to $28.74
• 52-Week Range: $18.77 to $30.42
• Volume: 2.54 million shs
• Average Volume: 2.64 million shs
• Market Capitalization: $3.87 billion
• P/E Ratio: 41.54
• Dividend Yield: N/A
• Price Target: $29.86
• Consensus Rating: Moderate Buy

Envista Stock Analysis - MarketRank™

Envista scored higher than 91% of companies evaluated by MarketBeat, and ranked 165th out of 901 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Envista has received a consensus rating of Moderate Buy. The company's average rating score is 2.53, and is based on 1 strong buy rating, 7 buy ratings, 9 hold ratings, and no sell ratings.

Upside Potential

Envista has a consensus price target of $29.86, representing about 23.9% upside from its current price of $24.09.

Amount of Analyst Coverage

Envista has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 7.84%

Earnings Growth

Earnings for Envista are expected to grow by 7.84% in the coming year, from $1.53 to $1.65 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Envista is 41.54, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.65.

Price to Earnings Ratio vs. Sector

The P/E ratio of Envista is 41.54, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.40.

Price to Earnings Growth Ratio

Envista has a PEG Ratio of 1.15. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Envista has a P/B Ratio of 1.28. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

6.42% of the float of Envista has been sold short.

Short Interest Ratio / Days to Cover

Envista has a short interest ratio ("days to cover") of 3.97, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Envista has recently decreased by 10.29%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Envista does not currently pay a dividend.

Dividend Growth

Envista does not have a long track record of dividend growth.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.27

News Sentiment

Envista has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 15 news articles for Envista this week, compared to 3 articles on an average week.

Search Interest

4 people have searched for NVST on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added Envista to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Envista insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $220,000.00 in company stock.

Percentage Held by Insiders

0.99% of the stock of Envista is held by insiders.

Percentage Held by Institutions

Envista has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/05/2026
• Today: 9/25/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Supplies
• Current Symbol: NYSE:NVST
• CIK: 1757073
• Web: www.envistaco.com
• Phone: (714) 817-5418
• Fax: 714-817-5450
• Employees: 12,000
• Year Founded: 2018

Price Target and Rating

• Average Price Target for Envista: $29.86
• High Price Target: $35.00
• Low Price Target: $23.00
• Potential Upside/Downside: +23.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.53
• Research Coverage: 17 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.58
• Trailing P/E Ratio: 41.54
• Forward P/E Ratio: 15.75
• P/E Growth: 1.15
• Net Income: $47 million
• Net Margins: 3.33%
• Pretax Margin: 8.20%
• Return on Equity: 7.88%
• Return on Assets: 4.33%

Debt

• Debt-to-Equity Ratio: 0.47
• Current Ratio: 2.43
• Quick Ratio: 2.07

Sales & Book Value

• Annual Sales: $2.72 billion
• Price / Sales: 1.42
• Cash Flow: $2.16 per share
• Price / Cash Flow: 11.14
• Book Value: $18.89 per share
• Price / Book: 1.28

Miscellaneous

• Outstanding Shares: 160,620,000
• Free Float: 159,028,000
• Market Cap: $3.87 billion
• Optionable: Optionable
• Beta: 0.86